通讯作者: 陈盈, m15990027483@163.com

DOI：10.12201/bmr.202604.00089

Research Progress in the Application of Mazdutide in the Obese Population

• 摘要：玛仕度肽作为首个胰高血糖素样肽-1与胰高血糖素双受体激动剂，通过延缓胃排空、抑制食欲及调节能量代谢等多重机制发挥减重作用。在单纯性超重或肥胖人群中，多项临床试验显示，玛仕度肽能显著降低体重、腰围，改善血糖、血脂、血压等代谢指标，且减重效果呈剂量依赖性。在肥胖合并2型糖尿病人群中，玛仕度肽表现出显著的减重与降糖双重效益，其疗效优于部分同类药物，且安全性与传统胰高血糖素样肽-1（Glucagon-Like Peptide-1，GLP-1）受体激动剂相似，常见不良反应以胃肠道反应为主。总体而言，玛仕度肽为肥胖及超重患者提供了一种有效且便利的药物选择，适用于生活方式干预效果不佳且伴代谢异常的成人患者。本文就玛仕度肽的作用机制、药动学特征、临床疗效与安全性等方面进行综述。

  关键词： 玛仕度肽; 双受体激动剂; 肥胖或超重; 减重

   

  Abstract: As the first dual agonist targeting both glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors, Mazdutide exerts significant weight loss effects through multiple mechanisms including delayed gastric emptying, enhanced satiety, suppressed appetite, and regulation of energy metabolism. In individuals with simple overweight or obesity, multiple clinical trials have demonstrated that Mazdutide can significantly reduce body weight, waist circumference, and body mass index (BMI), while improving metabolic indicators such as blood glucose, blood lipids, and blood pressure. The weight loss effect is dose-dependent. In populations with obesity and type 2 diabetes, Mazdutide also shows significant dual benefits in weight reduction and glucose lowering, with efficacy superior to some drugs of the same class and a safety profile similar to traditional GLP-1 receptor agonists. Common adverse reactions are mainly gastrointestinal, mostly mild to moderate, and more frequent during the dose escalation phase. Furthermore, clinical studies on Mazdutide in areas such as polycystic ovary syndrome and postoperative adjuvant therapy are underway, demonstrating its broad application potential. Overall, Mazdutide provides an effective and convenient pharmacological option for patients with obesity or overweight, particularly suitable for adults with poor response to lifestyle interventions and accompanying metabolic abnormalities. This article reviews the mechanism of action, pharmacokinetic characteristics, clinical efficacy, and safety profile of Mazdutide.

  Key words: Mazdutide; dual receptor agonist; obesity or overweight; loss weight

  提交时间：2026-04-10

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 费丽萍, 唐坎凯, 刘凤琪, 陈志冬. α7烟碱型乙酰胆碱受体激动剂对脓毒症小鼠肠损伤及线粒体自噬的影响. 2024. doi: 10.12201/bmr.202410.00066

  郭青霞, 张蕾. 右美托咪定经鼻给药在临床中的研究进展. 2024. doi: 10.12201/bmr.202409.00057

  程蕾. 中医中药在肠镜检查前肠道准备中的应用研究进展. 2026. doi: 10.12201/bmr.202601.00054

  阮偲琪, 李欣. 过氧化物酶体增殖活化受体γ与系统性红斑狼疮的研究进展. 2025. doi: 10.12201/bmr.202505.00007

  王羚钰, 徐红. 老年骨量-肌量减少性肥胖综合征的治疗进展. 2024. doi: 10.12201/bmr.202411.00064

  明晗文, 王强. Apelin在口腔疾病中的研究进展. 2026. doi: 10.12201/bmr.202603.00040

  张桢, 虞忻. 儿童结核病诊断中分子检测技术的应用与研究进展. 2025. doi: 10.12201/bmr.202506.00029

  陈烨, 覃燕红, 熊丽, 廖子龙, 陈日兰. 中医药调节肠道菌群对单纯性肥胖的研究进展. 2026. doi: 10.12201/bmr.202602.00011

  王子婕, 张鑫众. 叶酸受体阳性循环肿瘤细胞与非小细胞肺癌发生发展的研究进展. 2025. doi: 10.12201/bmr.202506.00024

  王馨雨, 张淑娟. GLP-2在非酒精性脂肪性肝病中的研究进展. 2025. doi: 10.12201/bmr.202502.00018

• 序号	提交日期	编号	操作
  1	2026-03-30	10.12201/bmr.202604.00089V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论